Clinical Trial Update: Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma [Phase 3]

View source ↗

Summary

This clinical trial update reports a Phase 3 study of subcutaneous epcoritamab with intravenous rituximab and oral lenalidomide (R2) in adults with follicular l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• EPKINLY (EPCORITAMAB-BYSP)
• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Genmab | Conditions: Follicular Lymphoma (FL) | Phase 3 | Status: ACTIVE_NOT_RECRUITING